Table 2.
Survival outcomes according to the systemic inflammation response index (SIRI) status and SIRI subgroups.
| Outcome | SIRI < 1.9 (N = 304) | SIRI ≥ 1.9 (N = 304) | P value | SIRI-1 (N = 171) | SIRI-2 (N = 345) | SIRI-3 (N = 92) | ∗ P value |
|---|---|---|---|---|---|---|---|
| PFS | |||||||
| Median, mo | 14.2 (12.8–15.6) | 9.0 (8.4–9.6) | <0.001 | 15.0 (13.2–16.8) | 11.1 (10.2–12.0) | 7.1 (6.3–7.9) | <0.001 |
| 5 years (%) | 7.4 | 16.0 | 19.8 | 9.8 | 0 | ||
| 10 years (%) | 3.1 | 10.8 | 14.9 | NR | 0 | ||
|
| |||||||
| OS | |||||||
| Median, mo | 30.3 (27.8–32.8) | 21.3 (19.5–23.1) | <0.001 | 36.7 (30.6–42.8) | 23.9 (22.3–25.5) | 13.8 (12.2–15.4) | <0.001 |
| 5 years (%) | 12.3 | 30.5 | 31.4 | 19.3 | 0 | ||
| 10 years (%) | 5.1 | 22.4 | 24.4 | 5.9 | 0 | ||
∗Bonferoni corrected P value <0.017 for significance. Note. SIRI-1: stage IIIB and SIRI < 1.9; SIRI-2: stage IIIB and SIRI ≥ 1.9 or stage IIIC and SIRI < 1.9; SIRI-3: stage IIIC and SIRI ≥ 1.9. Abbreviations. SIRI: systemic inflammation response index; PFS: progression-free survival; OS: overall survival.